Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Sichuan Kelun-Biotech Biopharmaceutical Co had a gross margin of 75.32% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Sichuan Kelun-Biotech Biopharmaceutical Co Gross Margin % Related Terms
Sichuan Kelun-Biotech Biopharmaceutical Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sichuan Kelun-Biotech Biopharmaceutical Co Gross Margin % Chart
Sichuan Kelun-Biotech Biopharmaceutical Co Annual Data
Trend
Dec21
Dec22
Dec23
Dec24
Dec25
Gross Margin %
36.50
65.57
49.28
65.89
71.86
Sichuan Kelun-Biotech Biopharmaceutical Co Semi-Annual Data
HKSE:06990 vs VRTX, REGN, RVMD: Gross Margin % Comparison
For the Biotechnology subindustry, Sichuan Kelun-Biotech Biopharmaceutical Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sichuan Kelun-Biotech Biopharmaceutical Co Gross Margin % vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) has a Gross Margin % of 75.32% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Sichuan Kelun-Biotech Biopharmaceutical Co and its competitors. This is 15% above median its historical median of 65.57. Over the past decade, Sichuan Kelun-Biotech Biopharmaceutical Co's Gross Margin % has ranged from 36.50 to 74.60. According to the industry distribution chart, Sichuan Kelun-Biotech Biopharmaceutical Co ranks #264 out of 735 companies in the Biotechnology industry, placing it in the top 35.9%.
Is Sichuan Kelun-Biotech Biopharmaceutical Co's Gross Margin % too high?
Sichuan Kelun-Biotech Biopharmaceutical Co's current Gross Margin % of 75.32% is 15% above median its 10-year median of 65.57. Over the past 10 years, this metric has ranged from a low of 36.50 to a high of 74.60. The Biotechnology industry median Gross Margin % is 60.96. Sichuan Kelun-Biotech Biopharmaceutical Co's value of 75.32% is 23.6% above this industry median. Based on the distribution chart, Sichuan Kelun-Biotech Biopharmaceutical Co ranks #264 out of 735 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sichuan Kelun-Biotech Biopharmaceutical Co has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sichuan Kelun-Biotech Biopharmaceutical Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sichuan Kelun-Biotech Biopharmaceutical Co ranks #264 out of 735 companies for Gross Margin %. This puts Sichuan Kelun-Biotech Biopharmaceutical Co in the upper half of its industry. The industry median Gross Margin % is 60.96. Sichuan Kelun-Biotech Biopharmaceutical Co's value of 75.32% is 23.6% above this benchmark. Historically, Sichuan Kelun-Biotech Biopharmaceutical Co's own Gross Margin % has ranged from 36.50 to 74.60 over the past decade. While the company's 10-year median is 65.57 vs. the industry median of 60.96, Sichuan Kelun-Biotech Biopharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.96, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sichuan Kelun-Biotech Biopharmaceutical Co's current Gross Margin % of 75.32% is 23.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Sichuan Kelun-Biotech Biopharmaceutical Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sichuan Kelun-Biotech Biopharmaceutical Co's current Gross Margin % is 75.32%, which is 15% above median its own 10-year median of 65.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sichuan Kelun-Biotech Biopharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$254.91, compared to a current price of HK$523.00 — trading 105.2% above its estimated fair value. The current Gross Margin % is 75.32%, which is 15% above median its 10-year median of 65.57 and 23.6% above the Biotechnology industry median of 60.96. Sichuan Kelun-Biotech Biopharmaceutical Co's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990), the current Gross Margin % is 75.32% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Overvalued in 2026?
Based on GuruFocus' analysis, Sichuan Kelun-Biotech Biopharmaceutical Co stock appears to be overvalued.
The current stock price of HK$523.00 is trading 105.2% above its estimated GF Value™ of HK$254.91.
GuruFocus considers Sichuan Kelun-Biotech Biopharmaceutical Co to be Significantly Overvalued.
Key valuation signals for HKSE:06990:
Gross Margin %: 75.32% (15% above median its 10-year median of 65.57)
GF Value™: HK$254.91 vs. price of HK$523.00 (105.2% above fair value)
Industry Position: 23.6% above the Biotechnology median (#264 of 735)
No single metric tells the full story. See the HKSE:06990 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a biopharmaceutical company committed to the R&D, manufacturing, and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population. Currently, the company has two ADC drugs as Core Products, namely, sac-TMT and trastuzumab botidotin.
44GF Score
Get the complete analysis for HKSE:06990
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06990 has been successfully added to your 
